Arbutus Biopharma's Entire Board Replaced as New CEO Steps In

Dow Jones

02-25

By Dean Seal

All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive.

The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board.

Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023.

McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing.

Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months.

Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

February 25, 2025 07:47 ET (12:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514099426"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514099426\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514099426?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514099426","market":"nz","top_or_hot":-1,"title":"Arbutus Biopharma's Entire Board Replaced as New CEO Steps In","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. \n</p>\n<p>\n  The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board. \n</p>\n<p>\n  Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023. \n</p>\n<p>\n  McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing. \n</p>\n<p>\n  Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months. \n</p>\n<p>\n  Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 07:47 ET (12:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma's Entire Board Replaced as New CEO Steps In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma's Entire Board Replaced as New CEO Steps In\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-25 20:47</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. \n</p>\n<p>\n  The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board. \n</p>\n<p>\n  Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023. \n</p>\n<p>\n  McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing. \n</p>\n<p>\n  Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months. \n</p>\n<p>\n  Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 07:47 ET (12:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABUS","symbol_name":"Arbutus Biopharma Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514099426","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514099426","pubTimestamp":1740487620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive.The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board.Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023.McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing.Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ABUS":"Arbutus Biopharma Corporation"},"translate_title":"Arbutus Biopharma的整个董事会被更换，新任首席执行官上任","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1},"content_text":"By Dean Seal \n\n\n \n\n\n  All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. \n\n\n  The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board. \n\n\n  Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023. \n\n\n  McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing. \n\n\n  Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months. \n\n\n  Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:47 ET (12:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1}}}